Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Next Previous
Trial Profile

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotrokinra (Primary) ; Deucravacitinib
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ICONIC-ADVANCE 1
  • Sponsors Janssen Research & Development

Most Recent Events

  • 17 Sep 2025 According to Johnson & Johnson Media Release, results of this trial will be presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress.
  • 17 Sep 2025 Results presented in the Johnson & Johnson Media Release.
  • 11 Sep 2025 According to Johnson & Johnson Media Release, the company has submitted an application to the EMA including data from 4 Phase 3 studies conducted as part of the ICONIC clinical development programme, including ICONIC-LEAD, ICONIC-TOTAL and ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top